News

Since it opened in 2005, until the final arms closed to recruitment in March 2023 almost 12,000 men have participated in the STAMPEDE trial across 10 different comparisons. Please follow this link for a breakdown of the recruitment figures: STAMPEDE Final Recruitment Figures. ...

It has previously been shown that adding the drug abiraterone to the standard hormone therapy just after diagnosis improves survival of people with prostate cancer that has spread to other parts of the body. New findings from the STAMPEDE trial have confirmed that use of abiraterone remains the best option without the addition of enzalutamide. These results from the STAMPEDE trial were published in Lancet Oncology in early May 2023. For more on this, please click on the following link to the MRCCTU news feed: Giving abiraterone at early stages helps people with advanced prostate cancer to live longer | MRC Clinical Trials Unit at UCL   ...

Investigators from the RADICALS and STAMPEDE clinical trials met before the ESMO 2022 conference to present and discuss their updated results. ...

Adding the drug abiraterone to standard hormone therapy helps people with prostate cancer that has spread to other parts of the body to live longer. Results from the STAMPEDE trial were presented at the European Society for Medical Oncology Congress in Paris last week. For more on this, please click on the following link to the UCL News feed: https://www.mrcctu.ucl.ac.uk/news/news-stories/2022/september/adding-abiraterone-to-standard-therapy-helps-people-with-metastatic-prostate-cancer-to-live-longer/ ...

UPDATE of NEW RESULTS, PROGRESS and FUTURE PLANSMonday 05-Sep-2022     12:00 – 14:00 GMTPlease contact mrcctu.stampede@ucl.ac.uk to register for the on-line meeting ...